Stock detail

Viatris (VTRS) stock price, chart, and key data

View Viatris stock price, chart movement, and headline metrics on Woodstock's stock detail page.

VTRS

Stock detail

Viatris

VTRS · XNAS

-$0.75 (-4.39%) past day

$16.34

Overnight $16.27 (-0.43%)

XNAS24/5 tradingLast updated: Jul 25, 01:01 PM

Key metrics

Earnings

Quarterly results and the next expected release

0.670.430.19-0.05-0.29
FY2025 Q2Reported EPS: 0.00Expected EPS: 0.62
FY2025 Q3Reported EPS: -0.11Expected EPS: 0.67
FY2025 Q4Reported EPS: -0.29Expected EPS: 0.57
FY2026 Q1Reported EPS: 0.15Expected EPS: 0.59
FY2026 Q2
FY2026 Q3

FY25 Q2

Q3

Q4

FY26 Q1

Q2

Q3

Reported EPSExpected EPS

Dividend

Past Dividend Performance

$0.12

$0.12

$0.12

2025/112026/32026/5

Annual Dividend Yield

2.94%

Dividend

$0.12 / Stock

Frequency

Quarterly Payment

Day range

$16.77 - $17.45

52-week range

$8.63 - $17.68

Close price

$17.28

Market cap

$20.1B

P/E ratio

-62.86

Beta

0.91

About the company

Viatris Inc.

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community. Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue.

Ticker holders

Review politician disclosures and insider transactions in tabs.

Holder directory

Select a heading to reorder by name, activity date, buy/sell, or displayed value.

10/10

#1Ro Khanna

democrat · House · CA-17

spouse
  • Sell$1,000 / $8,000 / $15,000
  • Buy$1,000 / $8,000 / $15,000
  • Sell$1,000 / $8,000 / $15,000
  • Buy$1,000 / $8,000 / $15,000
$4,000/$32,000/$60,000

#2Rob Bresnahan

republican · House · PA-8

self
  • Sell$1,001 / $8,001 / $15,000
  • Buy$1,000 / $8,000 / $15,000
$2,001/$16,001/$30,000

#3Ro Khanna

democrat · House · CA-17

child
  • Sell$1,000 / $8,000 / $15,000
$1,000/$8,000/$15,000

#4Ro Khanna

democrat · House · CA-17

self
  • Buy$1,000 / $8,000 / $15,000
$1,000/$8,000/$15,000

#5Gilbert Cisneros

democrat · House · CA-31

self
  • Buy$1,001 / $8,001 / $15,000
  • Sell$1,000 / $8,000 / $15,000
746/93/1,400

#6Laura Friedman

democrat · House · CA-30

self
2024
642/80/1,204

#7Debbie Wasserman Schultz

democrat · House

self
2024
642/80/1,204

#8James French Hill

republican · House · AR-2

self
2024
642/80/1,204

#9Michael Burgess

republican · House · TX-26

spouse
2023
46/1/92

#10Donald J Trump

republican · Executive

self
2026
30/1/61

Market action

A concise summary of the latest filing, transaction, or market-moving item.

Viatris Inc. director David S. Simmons reported an insider acquisition tied to his board compensation, not an open-market stock purchase or sale. On June 30, 2026, Simmons was automatically granted 2,362 deferred stock units, or DSUs, after electing to receive his quarterly non-employee director fees in equity rather than cash. The grant was valued using Viatris’ June 30 closing stock price of $15.88 per share. The transaction was reported on Form 4 filed July 1, 2026. The DSUs are derivative securities, with each unit representing the right to receive one share of Viatris common stock. The filing describes the award as fully vested at grant. Settlement will occur in Viatris common shares upon the earliest of Simmons’ termination of service as a non-employee director, his death or disability, or a change in control of the company. The reported transaction code is consistent with an acquisition of securities through an issuer compensation arrangement. Because the DSUs were granted in lieu of cash director fees, the filing does not indicate that Simmons bought shares in the market or sold any Viatris securities. Following the reported transaction, the filing reflects beneficial ownership of 2,362 DSUs associated with this award. The filing was signed on Simmons’ behalf by Kevin Macikowski under power of attorney on July 1, 2026.

24/5 Trading

Act on the stock when the timing works for you.

With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.

*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.

Download the app
24/5 trading chart preview

Sign Up

Scan the QR code to get started

Contact via LINE

Scan the QR code to get started

LINE QR Code